Lupin is increasing its focus on complex generics, biosimilars and specialty products as it seeks to sustain growth after a strong financial year. Vinita Gupta, CEO at Lupin told Business Today that ...

Netflix has delivered plenty of major hits over the years, including the likes of Stranger Things, Kpop: Demon Hunters and Squid Game, but one of its quieter hits has been the French drama, Lupin. The ...

Lupin has inked an agreement with Valorum for biosimilar Armlupeg. Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving ...

Netflix has revealed that Lupin Part 4 will premiere in fall 2026. Omar Sy will reprise his role as the gentleman thief Assane Diop in the fourth season. He will be joined in the cast by Ludivine ...

Netflix has confirmed that the French mystery thriller series Lupin, starring Omar Sy, will return for Part 4 in Fall 2026 The new season will consist of eight episodes and arrives approximately three ...

“Lupin,” Netflix’s French mystery thriller starring Omar Sy, will return with its fourth season in fall 2026. One of the most popular non-English-language series on Netflix, “Lupin” follows a master ...

GKIDS will be screening Lupin the IIIRD: The Immortal Bloodline from January 4 – 6, 2026 in select US theaters The film marks the 13th entry in the franchise, and the final entry in Takeshi Koike’s ...

Check out the Lupin the IIIRD: The Movie - The Immortal Bloodline trailer for this upcoming animated film and the latest chapter of the Lupin the IIIRD story from director and animator Takeshi Koike ...

Gov. Phil Murphy attended the ribbon-cutting ceremony for the 18,000-square-foot office space. Lupin, which specializes in respiratory care and complex generics, employs about 300 workers in New ...

Lupin is adding a U.S.-based pharmaceutical capacity to produce respiratory medicines. In recognition of its investment and job creation plans, Lupin will receive tax credits and incentives from the ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) said that the company and licensor SERB S.A. signed a settlement agreement with Lupin Pharmaceuticals, putting an end to a patent lawsuit. The lawsuit was in ...